Artiva Biotherapeutics (NASDAQ:ARTV) is prioritizing rheumatoid arthritis (RA) as the lead indication for its non-genetically ...

ImmunityBio stock gains more than 7% after completing two programs, showing scalable production of M-ceNK NK cells and early ...

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that new preclinical data for its proprietary SPiKE platform has been accepted ...

An iPSC manufacturing strategy for cell therapies drops the cost of goods sold to about $5,000 per dose, down from $115,000 per dose for autologous therapeutics and $40,000 per dose for allogeneic ...

Researchers have found a way to make cancer-killing immune cells more powerful and precise. By adding specific signaling components, they boosted the cells’ readiness to attack tumors. Surprisingly, ...

Expanded treatment in community settings will reduce patient burdenOption to redose patients granted in both Ntrust-1 and Ntrust-2 ...

Nkarta NKTX shares surged 15.7% on Thursday, reflecting strong investor optimism following a meaningful regulatory update tied to its lead autoimmune program, NKX019, an investigational CAR-NK cell ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio (IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, ...

A UCLA, research team has identified a genetic "brake" that prevents the body’s natural defense system from attacking solid tumors. By using CRISPR technology to delete a specific gene called FLI1, ...

A protein that helps cancer cells hide from the immune system may have a critical weakness, according to research that could ...